Navigation Links
Tongjitang Files 2009 Annual Report on Form 20-F
Date:7/1/2010

SHENZHEN, China, July 1 /PRNewswire-Asia-FirstCall/ -- Tongjitang Chinese Medicines Company (the "Company"; NYSE: TCM), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that it filed its Annual Report on Form 20-F for the year ended December 31, 2009 with the Securities and Exchange Commission on June 30, 2010. The Annual Report on Form 20-F can be accessed via the investor relations section of the Company's website at http://www.tongjitang.com .

The Company will provide a hard copy of its Annual Report on Form 20-F, including audited financial statements, free of charge to its shareholders and ADS holders upon request. Requests should be directed to the Company's Investor Relations contact at 203-682-8200.

About Tongjitang Chinese Medicines Company

Tongjitang Chinese Medicines Company, through its operating subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores, Guizhou Long-Life Pharmaceutical Company Limited, Qinghai Pulante and Anhui Jingfang, is a vertically integrated specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China. Tongjitang's principal executive offices are located in Shenzhen, China.

Tongjitang's flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi. In addition to Xianling Gubao, the Company manufactures and markets 36 other modernized traditional Chinese medicine products and 37 western medicines. Please visit http://www.tongjitang.com for more information.

    For further information, please contact:

    ICR, Inc.
     Ashley M. Ammon or Christine Duan
     Tel: +1-203-682-8200 (Investor Relations)


'/>"/>
SOURCE Tongjitang Chinese Medicines Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tongjitang Chinese Medicines Acquires Guiyang Liquor Factory
2. Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
6. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
7. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
8. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
9. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
10. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
11. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)...  Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), ... it entered into collaboration with Takeda Pharmaceutical Company ... of NASH and other gastrointestinal (GI) related disorders, ... UNA Oligomer chemistry. The financial terms were not ... and expertise in GI disorders, we are confident ...
(Date:12/6/2016)... , Dec. 6, 2016 A new study ... of 340B (AIR 340B) projects the 340B Drug Pricing Program ... by which time it is expected to exceed $23 billion ... would see 340B purchases surpass current Medicare Part B drug ... The new study – based on analysis of data on ...
(Date:12/6/2016)... Tenn , Dec. 6, 2016  In response ... dependent on opioids every 25 minutes, a respected group ... company that will provide a holistic suite of services ... Based on his own experience trying to ... social entrepreneur Justin Lanning launched 180 ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... ... of a higher risk of serious health problems, such as cardiovascular illness, according ... Peiman Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that the ...
(Date:12/6/2016)... , ... December 06, 2016 , ... An inventor, from ... utilize a sling, so she invented the patent-pending SLING-VEST. , The SLING-VEST provides an ... offers an improved alternative to traditional slings. As a result, it helps to reduce ...
(Date:12/6/2016)... ... December 06, 2016 , ... Mount Sinai Health System today ... of Neurosurgery, where clinicians can confer and order 3D models for their cases. ... basis with quick turnaround times. This resource will be the first of its ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Touchpoint Solution’s new neuroscience wearable, ... Almost 200 backers pledged more than $25,000 on Kickstarter to bring ... Dr. Amy Serin, an Arizona Neuropsychologist and inventor, says she feels like she stumbled ...
(Date:12/6/2016)... ... December 06, 2016 , ... After 30 years ... Susan Glasgow has announced her retirement from HASA at the end ... more than 4,000 individuals and families with hearing and speech services. She has ...
Breaking Medicine News(10 mins):